Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib

• Egile Nagusiak: Paweł Robak (Egilea), Edyta Węgłowska (Egilea), Izabela Dróżdż (Egilea), Damian Mikulski (Egilea), Dariusz Jarych (Egilea), Magdalena Ferlińska (Egilea), Ewa Wawrzyniak (Egilea), Małgorzata Misiewicz (Egilea), Piotr Smolewski (Egilea), Wojciech Fendler (Egilea), Janusz Szemraj (Egilea), Tadeusz Robak (Egilea)
• Formatua: Liburua
• Argitaratua: Hindawi Limited, 2020-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

The aim of the study was to determine the levels of selected cytokines and chemokines in the serum of multiple myeloma (MM) patients treated with bortezomib-based regimens. A total of 71 MM patients were examined: 41 with primary refractory disease (17) or early relapse (28), and 30 who were bortezo...